VBIO · XBRL financial data
Valion Bio financial statements, every fiscal year
The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (VBIO's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|
| Revenue | 1,840 | 1,176 | 780 | — |
| Cost of revenue | 1,541 | 889 | 778 | — |
| Gross profit | 299 | 287 | 2 | — |
| Research and development | 1,730 | 1,655 | 1,313 | 3,131 |
| Selling, general and administrative | — | — | 3,163 | 4,767 |
| General and administrative | 5,875 | 4,752 | 3,163 | — |
| Total operating expenses | 10,397 | 8,532 | 5,663 | 7,898 |
| Operating income (loss) | (10,098) | (8,245) | (5,661) | (7,898) |
| Interest income | — | — | 6 | 23 |
| Interest expense | — | — | 0 | 146 |
| Income tax expense (benefit) | — | — | 0 | 0 |
| Net income (loss) | (10,096) | (8,244) | (5,655) | (8,878) |
| Earnings per share, basic‡ USD per share | (1,768.71) | (176.87) | (334.69) | (7.84) |
| Earnings per share, diluted‡ USD per share | (1,768.71) | (176.87) | (334.69) | — |
| Weighted average shares, basic‡ thousands of shares | 6 | 47 | 17 | 1,156 |
| Weighted average shares, diluted‡ thousands of shares | 6 | 47 | 17 | — |
- ‡ Per-share figures and share counts are adjusted for the 1-for-100 stock split (August 2023); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-17.006802721088437 stock split (March 2025); filings made before it reported them unadjusted.
- † Share count changed about 5x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 79x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (VBIO's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | 3,517 | 3,395 | 2,002 | 12,645 |
| Accounts receivable | 88 | 174 | 69 | — |
| Inventory | 863 | 756 | 319 | 0 |
| Prepaid and other current assets | 235 | 327 | 249 | 346 |
| Total current assets | 5,287 | 4,652 | 2,639 | 13,006 |
| Property and equipment, net | 12 | 122 | 119 | 12,641 |
| Right-of-use asset | 523 | 349 | — | 0 |
| Goodwill | — | — | 0 | 3,457 |
| Total assets | 5,856 | 5,157 | 2,807 | 31,607 |
| Accounts payable | 1,323 | 713 | 125 | 264 |
| Total current liabilities | 1,859 | 1,401 | 272 | 646 |
| Lease liability, non-current | 367 | 176 | — | 0 |
| Total liabilities | 2,226 | 1,577 | 272 | 7,440 |
| Accumulated deficit | (29,642) | (37,886) | (43,541) | (52,597) |
| Total stockholders' equity | 3,630 | 3,580 | 2,535 | 16,797 |
| Total liabilities and equity | 5,856 | 5,157 | 2,807 | 31,607 |
| Common shares outstanding (cover page)‡ thousands of shares | 17 | 86 | 36 | 2,878 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-100 stock split (August 2023); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-17.006802721088437 stock split (March 2025); filings made before it reported them unadjusted.
- † Share count changed about 5x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 79x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (VBIO's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|
| Net income (loss) | (10,096) | (8,244) | (5,655) | (8,878) |
| Stock-based compensation | 398 | 271 | 229 | 564 |
| Depreciation and amortization | 10 | 8 | 3 | — |
| Net cash from operating activities | (8,919) | (8,511) | (5,725) | (6,999) |
| Purchases of property and equipment | 11 | 118 | 0 | 38 |
| Net cash from investing activities | (11) | (118) | 0 | (705) |
| Proceeds from issuing common stock | — | 8,507 | 4,381 | 2,337 |
| Net cash from financing activities | (528) | 8,507 | 4,332 | 18,347 |
| Net change in cash | (9,458) | (122) | (1,393) | 10,643 |
- † Share count changed about 5x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 79x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Valion Bio | 2,108 | not reported | (5,281)* | 22.2M | 0.4 quarters | 10-QJun 30, 2026 |
| Healthy Extracts | 190 | 2,067 | 306* | 14.7M | — | 10-QJun 30, 2026 |
| Theriva Biologics | 11,337 | 0* | (3,085)* | 45.9M | 3.7 quarters | 10-QJun 30, 2026 |
| Jaguar Health | 3,788 | 1,225 | (5,338)* | not reported | 0.7 quarters | 10-QJun 30, 2026 |
| China Pharma Holdings | 305 | 948 | (33)* | 43.0M | 9.3 quarters | 10-QJun 30, 2026 |
| Synlogic | 13,183 | 0 | (922)* | 12.2M | 14.3 quarters | 10-QJun 30, 2026 |
| Q/C Technologies | 308 | not reported | (1,819)* | 8.2M | 6.0 quarters | 10-QJun 30, 2026 |
| Polomar Health Services | 179 | 1,529 | 121* | 28.4M | — | 10-QJun 30, 2026 |
| Enveric Biosciences | 8,296 | not reported | (2,445)* | 4.5M | 3.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.